On Wednesday, GSK signed a multi-year licensing agreement with British biotech company Ochre Bio to develop new avenues of treatment for liver disease.

Under the terms of the agreement, the American biopharmaceutical group will have access to Ochre Bio's proprietary data platforms, notably based on organ perfusions.

GSK - one of whose priority areas of development is hepatology - says it wants to deepen its knowledge in this field.

More specifically, the data collected by GSK will be used in AI models with the aim of identifying potential targets.

The agreement is valued at a total of £37.5 million (around €44 million).

Copyright (c) 2024 CercleFinance.com. All rights reserved.